Pharmacovigilance

Venue: Crowne Plaza London

Location: London, United Kingdom

Event Date/Time: Mar 15, 2010 End Date/Time: Mar 16, 2010
Report as Spam

Description

The importance of developing effective pharmacovigilance systems has been fuelled by an increased focus on drug safety and the ever-changing regulatory environment. This conference will tackle inspections, risk management, the use of Independent Data Monitoring Committees and establishing relationships with regulatory bodies along with a host of other key topics.


Reasons to Attend

• Hear the latest updates on various pharmacovigilance systems in the industry
• Explore ways in which you can optimise your own pharmacovigilance activities
• Discuss the potential impact of impending regulatory changes
• Network with industry associates and discuss experiences


Presentations Include:

• THE FUTURE OF PHARMACOVIGILANCE IN THE EU
Elmar Kroth, Head of Pharmacovigilance, German Medicines Manufacturers' Association

• INTERNAL AUDIT STRATEGY FOR PHARMACOVIGILANCE
Benoit Nauge, Senior Manager, Global Compliance Auditing, Amgen

• PHARMACOVIGILANCE INSPECTIONS BY NATIONAL HEALTH AUTHORITIES
Dominique Brunier, Head of Pharmacovigilance and Quality, Europe, Novartis

Our expert speaker line-up includes:

• Andrew P. Marr, Director, Global Regulatory Operations, GlaxoSmithKline
• Jacques Wodelet, Head of Quality Intelligence, Merck Serono
• Nicky Wallis, Medical Director, Oncology, Pfizer
• Petra Heyen, Vice President, Regulatory Affairs and PharmacoVigilance, Therabel Pharma
• Leann Fieldstad, Global Head Compliance, F. Hoffmann–La Roche
• Ceri Deveney, Director, Pharmacovigilance, MedImmune
• Lucy Hampshire, Quality Consultant, Eli Lilly
• Sian Ratcliffe, Senior Director, Safety and Risk Management Lead, Pfizer


Plus a half-day pre-conference workshop:
Pharmacovigilance Inspections: A Practical Approach
17th March 2010, Crowne Plaza London - St James, UK
Hosted by Colin Knight of Transcrip Partners

Venue